GlassScriptPhysician profile
James W Stephens
NPI 1235459413
$39,116.20
in general payments reported to CMS, 2019-2025
50 companies · $2,053 in 2025
The $2,053 reported for 2025 was more than what 80% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $7,430 · 2021: $9,212 · 2022: $4,418 · 2023: $1,472 · 2024: $4,234 · 2025: $2,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,258 · Consulting Fee: $2,000 · Travel and Lodging: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,258.27 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $9,383.05 | 2020-2025 | Ha Minuteman G3-R |
| Vertiflex, INC. | $8,814.93 | 2019 | |
| Boston Scientific Corporation | $8,148.09 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept, Cre Pro |
| Southern Spine, LLC | $5,325.38 | 2021 | |
| Nevro Corp. | $1,012.26 | 2019-2024 | Senza |
| Abbott Laboratories | $887.86 | 2019-2025 | Eterna, Proclaim |
| Relievant Medsystems, INC. | $885.64 | 2019-2023 | Intracept |
| Medtronic, INC. | $813.56 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Forte Bio-Pharma LLC | $457.20 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Globus Medical, INC. | $447.83 | 2025 | Senza, Vyrsa V1 |
| Si-Bone, INC. | $445.70 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $284.68 | 2022-2025 | Belbuca |
| Stryker Corporation | $280.04 | 2019-2025 | Gamma, Spinejack |
| Protega Pharmaceutials INC | $187.42 | 2025 | Roxybond |
| Mml US, INC. | $185.85 | 2023 | Reactiv8 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.